证券代码：600329 证券简称：达仁堂 编号：临 2024-042 号 津药达仁堂集团股份有限公司 关于第六次回购注销部分限制性股票 通知债权人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、 通知债权人的理由 债权申报所需材料：公司债权人可持证明债权债务关系存在的合同、协议及 其他凭证的原件及复印件到公司申报债权。债权为法人的，需同时携带法人营业 执照副本原件及复印件、法定代表人身份证明文件；委托他人申报的，除上述文 件外，还需携带法定代表人授权委托书和代理人有效身份证的原件及复印件。债 权人为自然人的，需同时携带有效身份证的原件及复印件；委托他人申报的，除 上述文件外，还需携带授权委托书和代理人有效身份证件的原件及复印件。 债权申报具体方式如下： 4、联系电话：022-27020892 5、传真号码：022-27020892 特此公告。 津药达仁堂集团股份有限公司董事会 津药达仁堂集团股份有限公司（以下简称"公司"）于 2024 年 11 月 11 日 召开 2024 年第八次董事会和 2024 年第五次监事 ...

证券代码：600329 证券简称：达仁堂 编号：临 2024-037 号 津药达仁堂集团股份有限公司于 2024 年 11 月 11 日以通讯方式 召开了 2024 年第八次董事会会议。本次会议应参加董事 9 人，实参 加董事 9 人。会议召开符合《公司法》、《证券法》和《公司章程》有 关召开董事会会议的规定。会议形成如下决议： 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、审议通过了《关于第五次调整公司 2019 年 A 股限制性股票 激励计划回购价格并第六次回购注销已获授但尚未解除限售的限制 性股票的议案》。（详见临时公告 2024-039 号） 根据《公司 2019 年 A 股限制性股票计划（草案）》（简称"《激 励计划》"）、《公司 2019 年 A 股限制性股票激励计划实施考核管理办 法》的相关规定，因公司 2023 年年度权益分派实施完毕，公司首次 授予及预留授予的限制性股票回购价格分别调整为 3.70 元/股和 5.69 元/每股。由于首次授予激励对象中 5 名激励对象全部未达到《激励 计划》中第三个解除限 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected stock price increase of over 15% relative to the industry index within the next six months [6][17]. Core Views - The industrial segment continues to show steady performance, with profit growth turning positive year-on-year. The company reported a revenue of 56.1 billion yuan for the first three quarters of 2024, a decrease of 3.1% year-on-year, while the net profit attributable to shareholders was 8.0 billion yuan, down 6.3% year-on-year [1][2]. - The company plans to transfer a 13% stake in a subsidiary, which is expected to improve cash flow and focus on core business expansion. The transaction is projected to impact investment income by approximately 1.7 billion yuan [3][6]. - The company is enhancing its marketing structure and focusing on channel penetration and regional expansion, which is expected to drive sales growth of key products [3][6]. Financial Summary - **Revenue and Profitability**: The company achieved a revenue of 8,222 million yuan in 2023, with a slight decline of 0.3% compared to 2022. The projected revenue for 2024 is 8,277 million yuan, with a growth rate of 0.7% [1][10]. - **Net Profit**: The net profit attributable to shareholders for 2023 was 987 million yuan, reflecting a year-on-year increase of 14.5%. The forecast for 2024 is 1,023 million yuan, with a growth rate of 3.6% [1][10]. - **Key Financial Ratios**: The return on equity (ROE) for 2023 was 14.6%, with projections of 15.4% for 2024. The earnings per share (EPS) for 2023 was 1.28 yuan, expected to rise to 1.33 yuan in 2024 [1][11]. Segment Performance - **Industrial Segment**: The industrial segment reported a revenue of 35.9 billion yuan for the first three quarters of 2024, an increase of 4.3% year-on-year. The commercial segment, however, faced challenges with a revenue decline of 14.5% [2][6]. - **Gross Margin Improvement**: The gross margin for Q3 2024 improved to 46.7%, up 6.6 percentage points year-on-year, attributed to better business structure [2][6]. Future Outlook - The company is expected to see net profits of 10.2 billion yuan, 11.8 billion yuan, and 13.3 billion yuan for the years 2024, 2025, and 2026 respectively. The EPS is projected to be 1.3 yuan, 1.5 yuan, and 1.7 yuan for the same years [6][12].

Investment Rating - The report maintains a "Recommended" rating for the company, with a target price of 39.8 CNY [1][2]. Core Insights - The company has shown stable industrial growth, although its commercial segment has experienced a decline. The industrial revenue for the first three quarters of 2024 decreased by 14.5% year-on-year, while the commercial segment's revenue reached 23.3 billion CNY [1][2]. - The company is actively implementing a new marketing model that integrates online and offline sales channels, focusing on the southern market and aiming to cover 18,000 pharmacies through a refined marketing structure [1][2]. - Financial indicators remain robust, with a gross margin increase to 46.6% and a net profit margin of 11.8% for the third quarter of 2024 [1][2]. Financial Performance Summary - For the first three quarters of 2024, the company reported total revenue of 56.1 billion CNY, a decrease of 8.9% year-on-year. The net profit attributable to the parent company was 8.0 billion CNY, reflecting a decline of 3.4% [1][2]. - The company expects a net profit of 10.4 billion CNY, 12.2 billion CNY, and 14.5 billion CNY for the years 2024, 2025, and 2026 respectively, with growth rates of 5%, 18%, and 18% [1][2]. - The projected earnings per share (EPS) for 2024, 2025, and 2026 are 1.35 CNY, 1.59 CNY, and 1.88 CNY respectively, indicating a positive growth trajectory [2]. Valuation Metrics - The report provides a price-to-earnings (P/E) ratio forecast of 25 for 2024, decreasing to 21 by 2025 and further to 18 by 2026 [2]. - The price-to-book (P/B) ratio is expected to remain stable at around 4 for the next three years [2]. Market Positioning - The company is focusing on enhancing its marketing structure and professional operations, aiming to strengthen its market presence and adapt to market demands [1][2]. - The report highlights the company's commitment to academic and professional promotion strategies, which are expected to yield positive results in the long term [1][2].

Financial Performance - Total revenue for Q3 2024 was ¥1,646,191,771.12, a decrease of 3.43% compared to the same period last year[2] - Net profit attributable to shareholders was ¥146,136,561.08, an increase of 7.69% year-on-year[2] - Net profit excluding non-recurring items was ¥132,928,496.57, up 2.46% from the previous year[2] - Operating profit for the first three quarters of 2024 was CNY 919,432,930.61, compared to CNY 961,951,114.63 in 2023, indicating a decline of 4.42%[20] - Net profit for the first three quarters of 2024 was CNY 793,134,205.47, down from CNY 842,024,243.32 in 2023, representing a decrease of 5.79%[20] - The net profit attributable to the parent company for Q3 2024 is approximately ¥803.86 million, a decrease from ¥858.19 million in Q3 2023, representing a decline of about 6.3%[21] - The total comprehensive income for Q3 2024 is approximately ¥792.45 million, compared to ¥842.86 million in Q3 2023, indicating a decrease of around 5.9%[21] - Basic and diluted earnings per share for Q3 2024 are both ¥1.04, a decrease from ¥1.11 in Q3 2023, reflecting a decline of about 6.3%[21] Cash Flow and Investments - Operating cash flow for the quarter was ¥12,394,444.80, a significant increase of 130.05% compared to the same period last year[3] - Cash flow from operating activities for the first nine months of 2024 is approximately ¥6.20 billion, slightly down from ¥6.20 billion in the same period of 2023[22] - The net cash flow from operating activities for the first nine months of 2024 is approximately ¥567.61 million, a significant increase from ¥81.18 million in the same period of 2023[22] - Cash outflow from investing activities for the first nine months of 2024 is approximately ¥1.39 billion, compared to ¥713.65 million in the same period of 2023, indicating a substantial increase in investment spending[23] - The net cash flow from financing activities for the first nine months of 2024 is approximately -¥31.52 million, an improvement from -¥377.51 million in the same period of 2023[23] Assets and Liabilities - Total assets increased to ¥10,969,529,949.24, reflecting a growth of 7.23% from the end of the previous year[3] - Total assets as of the end of the third quarter of 2024 amounted to CNY 10,969,529,949.24, an increase of 7.25% from CNY 10,230,100,940.68 at the end of 2023[19] - Total liabilities as of the end of the third quarter of 2024 were CNY 4,515,635,865.06, up from CNY 3,584,864,433.55 in 2023, reflecting an increase of 25.92%[19] - The company's cash and cash equivalents at the end of the third quarter of 2024 were CNY 1,023,295,255.00, significantly higher than CNY 81,800,000.00 at the end of 2023[19] Shareholder Information - The total number of common shareholders at the end of the reporting period is 48,429, with the largest shareholder, Tianjin Pharmaceutical Group Co., Ltd., holding 331,120,528 shares, representing 42.994% of the total[10] - The company has a significant shareholder structure, with ABN AMRO CLEARING BANK N.V. holding 72,878,700 shares, accounting for 9.463%[10] - The total number of shares held by the top ten shareholders includes 325,855,528 shares of unrestricted circulating stock[12] - The company reported no significant changes in the shareholder structure due to securities lending activities[15] Operational Metrics - The company's industrial segment revenue reached ¥3.59 billion, a year-on-year increase of 4.3%, while the commercial segment revenue was ¥2.33 billion, down 14.5%[7] - Research and development expenses for the first three quarters of 2024 were CNY 98,797,435.21, compared to CNY 86,494,285.36 in 2023, marking an increase of 14.00%[20] - The company reported a decrease in sales expenses to CNY 1,475,052,433.95 in 2024 from CNY 1,454,601,997.58 in 2023, a slight reduction of 1.40%[20] - Deferred income tax assets increased to CNY 301,856,506.84 in 2024 from CNY 265,992,670.23 in 2023, an increase of 13.48%[19] Cash and Cash Equivalents - The company's cash and cash equivalents as of September 30, 2024, amount to approximately CNY 1.45 billion, a decrease from CNY 2.13 billion at the end of 2023[17] - Cash and cash equivalents at the end of Q3 2024 amount to approximately ¥1.36 billion, down from ¥1.93 billion at the end of Q3 2023[23] - Cash and cash equivalents decreased by 31.55% due to increased cash payments for large deposits[9] Government Subsidies - The company received government subsidies amounting to ¥1,723,185.35 during the reporting period[5] Other Information - The company has not disclosed any new strategies or product developments during the reporting period[16] - The company has not participated in margin trading or securities lending activities during the reporting period[13]

证券代码：600329 证券简称：达仁堂 公告编号：2024-036 号 津药达仁堂集团股份有限公司 2024 年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 704 | | --- | --- | | 其中：A 股股东人数 | 685 | | 境外上市外资股股东人数（S 股） | 19 | | 2、出席会议的股东所持有表决权的股份总数（股） | 17,503,747 | | 其中：A 股股东持有股份总数 | 15,687,637 | | 境外上市外资股股东持有股份总数（S 股） | 1,816,110 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 2.273 | (一) 股东大会召开的时间：2024 年 10 月 29 日 (二) 股东大会召开的地点：中国天津市南开区白堤路 17 号达仁堂大厦会议室 (三) 出席会议的普通股股东和恢复表 ...

北京观韬（天津）律师事务所 GUANTAO LAW FIRM·TIAN JIN OFFICE 中国天津市和平区大沽北路与徐州道交口 万通中心 6 层 609-611 邮编：300042 Tel：86 22 58299677/78 Fax：86 22 58299679 E-mail：guantaotj@guantao.com http：// www.guantao.com Room609-611,Floor 6,Vantone Central,, Heping District, Tianjin 300042, P.R. China 北京观韬（天津）律师事务所 关于津药达仁堂集团股份有限公司 2024 年第一次临时股东会的法律意见书 观意字【2024】第 007574 号 致：津药达仁堂集团股份有限公司 北京 · 上海 · 西安 ·成都 · 大连 · 深圳 ·济南 · 厦门 · 香港 · 天津 · 广州· 杭州 Beijin · Shanghai · Xi'an · Chengdu · Dalia · Shenzhen · Jinan · Xiamen · Hong Kong·Tianjin·GuangZhou ...

证券代码：600329 证券简称：达仁堂 公告编号：2024-035 号 津药达仁堂集团股份有限公司 关于召开 2024 年第一次临时股东大会的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东大会类型和届次 2024 年第一次临时股东大会 召开的日期时间：2024 年 10 月 29 日 14 点 00 分 召开地点：中国天津市南开区白堤路 17 号达仁堂大厦会议室 (五) 网络投票的系统、起止日期和投票时间。 股东大会召开日期：2024年10月29日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 (四) 现场会议召开的日期、时间和地点 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2024 年 10 月 29 日 至 2024 年 10 月 29 日 | 序号 | 议案名称 | 投票股东类型 | | ...

津药达仁堂集团股份有限公司 2024 年第一次临时股东大会 会议资料 2024 年 10 月 29 日 2024 年第一次临时股东大会 文件目录 目 录 现场会议召开时间：2024 年 10 月 29 日下午 2:00 会议方式：现场投票和网络投票相结合的方式 会议地点：中国天津市南开区白堤路 17 号达仁堂大厦会议室 | 序号 | 议案 | 页码 | | --- | --- | --- | | 1 | 公司对津药太平医药有限公司增资暨签订《增资协议》的关联交易议 | 3 | | | 案 | | | 2 | 根据新加坡交易所《上市手册》，增资完成后的津药太平医药有限公 | 18 | | | 司形成合资关系的关联人交易议案 | | | 3 | 公司为天津中新医药有限公司存续担保履行关联担保审议程序的关 | 19 | | | 联交易议案 | | 2 2024 年第一次临时股东大会 议案一 议案 1：关于公司对津药太平医药有限公司增资暨签订 《增资协议》的关联交易议案 公司于 2024 年 9 月 10 日召开 2024 年第五次董事会，会议审议 通过了"公司对津药太平医药有限公司增资暨签订《津药达仁堂集团 股份有 ...

Investment Rating - The report maintains a rating of "Accumulate" for the company [3][10]. Core Insights - The company is a leading inheritor of traditional Chinese medicine, with well-known products such as the "Suxiao Jiuxin Wan" and "Jingwanhong Ointment" [2][16]. - The company has a rich product portfolio with 599 approved drug varieties and 223 items listed in the national medical insurance catalog [2][16]. - The company focuses on three core areas: cardiovascular health, skin wound repair, and premium traditional Chinese medicine health products, aiming to become an innovative leader in traditional Chinese medicine [2][16]. - The sales of "Suxiao Jiuxin Wan" exceeded 2 billion yuan in 2023, with strong growth momentum and potential for further volume and price increases [2][10]. - "Jingwanhong Ointment" has expanded its application to treat diabetic foot ulcers and has achieved significant sales growth, reaching 828 million boxes sold in 2023, a year-on-year increase of 64.66% [2][10]. Summary by Sections 1. Traditional Chinese Medicine Inheritance - The company is a state-level high-tech enterprise with a history of over 500 years, focusing on green Chinese medicine and covering the entire industry chain from cultivation to production [16][18]. - It holds six well-known trademarks and has several national-level intangible cultural heritage projects [2][16]. 2. Focus on "Three Cores and Nine Wings" Product Strategy - The first core is the "Chinese Heart" series, led by "Suxiao Jiuxin Wan," which has a strong brand presence in the cardiovascular market [23][24]. - The second core is the "Chinese Skin" series, represented by "Jingwanhong Ointment," which is a unique product for skin health [23][24]. - The third core includes products aimed at anti-aging and memory improvement, such as "Niuhuang Qingxin Wan" and "Qinggong Shoutao Wan" [23][24]. 3. Focus on Main Business and Equity Transfer - The company plans to transfer its equity in Tianjin Shike to focus on its main business, which is expected to generate approximately 1.7 billion yuan in investment income [63][63]. 4. Profit Forecast and Investment Recommendations - The company is projected to achieve revenues of 89.98 billion yuan, 97.10 billion yuan, and 103.90 billion yuan in 2024, 2025, and 2026, respectively, with corresponding net profits of 11.90 billion yuan, 13.79 billion yuan, and 15.68 billion yuan [10][67]. - The report suggests an "Accumulate" rating based on the expected growth in revenue and profit [10][68].